DYDmitry E. Yurov

Dmitry E. Yurov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry E. Yurov has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antidepressants and older age: risks of pharmacotherapy

    by German V. Kukushkin, Dmitry E. Yurov, Elena V. Kalinina, Ekaterina E. Burenkova, Daniil A. Devushkin, Юров Дмитрий Евгеньевич

    High prevalence of depression among older adults is a significant global public health concern. The situation is further aggravated by population aging, which increases the number of individuals requiring care. Alongside with psychotherapy, pharmacotherapy is widely used in depression management. However, its use in older adults poses substantial challenges due to age-related physiological changes and an elevated risk of adverse drug reactions. Multimorbidity and associated polypharmacy further contribute to the likelihood of harmful drug-drug interactions. In addition, aging-related changes affect drug elimination. Various classes of antidepressants with generally comparable efficacy are available on the pharmaceutical market. Tricyclic antidepressants, such as amitriptyline and imipramine, are not recommended in older adults due to a high incidence of adverse effects, including sedation, dry mouth, constipation, and orthostatic hypotension. Serotonin reuptake inhibitors, such as fluoxetine, sertraline, and citalopram, have a more favorable safety profile and are considered first-line agents in the treatment of depression in the elderly, although they are not without drawbacks. Selective serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine, act on two neurotransmitter systems, which may increase the likelihood of adverse effects. Atypical antidepressants (mirtazapine, trazodone, vortioxetine, and agomelatine) constitute a heterogeneous group of agents that differ in their mechanisms of action and safety profiles. Thus, when treating older adults, the rational choice of an antidepressant should consider its side effect profile, potential drug interactions, comorbid conditions, and cost of therapy.

  • THE POSSIBILITIES OF USING PROTEOLYTIC ENZYMES IN LYMPHOTROPIC THERAPY

    by Kukushkin G.V., Zhuravleva M.V., Yurov D.E.

    Proteolytic enzymes have a variety of pharmacological effects, which determines their important role and place in clinical medicine. The aim of this study was to confirm the lymphostimulating effect of terrilytin, an integral part of the drug terridecase, and to study its effect on the pharmacokinetic parameters of cefotaxime. Materials and methods of research. Assessment of the rate of lymphatic drainage in the mesentery of mice by the time of removal of lymphotropic dye from it; determination of the concentration of the antibiotic cephalosporin antibiotic of the third generation cefotaxime in rabbit blood plasma during the day, blood plasma, intestinal tissues and liver of white mongrel mice after 1.5 and 24 hours of experiment by high-performance liquid chromatography. Results. It has been confirmed that terrilytin has a lymphostimulating effect. It has been established that this proteolytic enzyme has the properties of an endolymphatic conductor. Its preliminary administration increases the concentration of cefotaxime in the blood plasma of rabbits and mice compared with monovision of the antibiotic at all time points of the study, up to a day, and increases its content in the intestinal tissue of mice, both 1.5 hours and 24 hours after injection of drugs. Terrilytin does not affect the level of cefotaxime in the liver tissue of mice, but reduces the ratio of its concentrations "liver tissue/blood", which indirectly indicates a decrease in liver extraction of the antibiotic. Conclusion. Terrilytin in clinical practice was used topically (externally or electrophoretically), whereas our studies were conducted against the background of its parenteral administration. This obstacle can be overcome by using a polyglucine–modified form of terrilytin – terridecase, which is allowed for parenteral administration. In this regard, it is advisable to continue studying the combined drug terridecase in order to identify its ability to direct water-soluble antibiotics into the lymphatic system.

  • Open Access

    Influence of drugs with hyaluronidase activity on the survival of animals with a purulent-inflammatory process in the abdominal organs

    by German V. Kukushkin, Marina V. Zhuravleva, Dmitry E. Yurov, Юров Дмитрий Евгеньевич

    BACKGROUND: The optimization of the pharmacokinetics of antibiotics is an important aspect in improving the effectiveness of therapy for intra-abdominal infections. Thus, studying the survival of experimental animals with a simulated purulent-inflammatory process in abdominal organs using the combined use of antibacterial agents with endolymphatic agents is worthwhile. AIMS: To examine the effect of the co-administration of cefotaxime and hyaluronidase or bovgyaluronidase azoximer on the survival of mice with a purulent-inflammatory process of the abdominal organs. MATERIALS AND METHODS: The purulent-inflammatory process of the abdominal organs, which was simulated by the intraperitoneal administration of a lethal dose of Staphylococcus aureus microbial suspension to mice, was evaluated. Four study groups were formed, with 28 animals each. Group 1 did not receive treatment, group 2 was administered with cefotaxime, and groups 3 and 4 received antibiotics after preliminary administration of hyaluronidase or bovgialuronidase azoximer. For the statistical analysis of animal survival, the Kaplan–Meier multiple assessment method was used, and a univariate analysis using a log-rank test was employed to identify significant differences between the groups. RESULTS: During the study, a single injection of cefotaxime alone and in combination with other studied drugs promoted the survival of some mice with a simulated purulent-inflammatory process of the abdominal organs compared with the untreated group, and at the end of the experiment (day 7), 100% of the animals died. Moreover, the best results were achieved with the initial administration of hyaluronidase or bovhyaluronidase azoximer. Thus, on day 7 of observation, 70% of the animals in groups that received both an antibiotic and hyaluronidase or bovgyaluronidase azoximer survived. No statistically significant differences were found in the effect of these drugs on animal survival in the presence of an experimental purulent-inflammatory process. CONCLUSION: A single injection of cefotaxime alone or in combination with other studied drugs ensures the survival of some mice with a simulated purulent-inflammatory process of the abdominal cavity compared with the control group, in which 100% of the animals died by the end of the experiment (day 7). Moreover, the best results were achieved in groups initially administered with hyaluronidase or bovgialuronidase azoximer.

  • Side effects of drugs recommended for the treatment of harmful alcohol use

    by Boris K. Romanov, Gulnara O. Dibirova, Natalia B. Dmitrieva, Elena V. Kalinina, Anna V. Kirillova, Elena V. Markina, Svetlana E. Mileshina, Andrey S. Sokolov, Maia D. Tsitsuashvili, Dmitry E. Yurov, et al.

    This brief report provides an overview of pharmacovigilance information on adverse reactions during post-registration use of medicines recommended for the treatment of mental and behavioral disorders caused by alcohol consumption in the Russian Federation, and its reports were included in the database of the World Health Organizations international drug monitoring program as of January 1, 2023. The safety indicators of benzodiazepines, phenobarbital, butyrophenones, anticonvulsants, thiamine, and magnesium preparations were analyzed. The article may be of interest to pharmacovigilance specialists, doctors, researchers, developers and health regulators, pharmacologists, and clinical pharmacologists.

  • Antibiotic treatment failure

    by Sergey P. Alpatov, Nadezhda V. Bogush, Denis A. Borozdenko, Natalia M. Buyanova, Irina V. Ganshina, Gulnara O. Dibirova, Natalia B. Dmitrieva, Elena V. Kalinina, Anna V. Kirillova, Nina M. Kiseleva, et al.

    This review presents information on cases of antibiotic failure (insufficient effect) in the global population over the past three years. We analyzed scientific papers, clinical trial data, and the WHO Program for International Drug Monitoring (VigiBase) data from 2018 to 2020. The values of global success and safety rates of antibacterial drugs for medical use are presented. The findings may be of practical interest to physicians, researchers, developers, and healthcare regulators.

  • Vaccine safety for COVID-19 prevention

    by Boris K. Romanov, Sergey P. Alpatov, Nadezhda V. Bogush, Denis A. Borozdenko, Natalia M. Buyanova, Irina V. Ganshina, Gulnara O. Dibirova, Natalia B. Dmitrieva, Elena V. Kalinina, Anna V. Kirillova, et al.

    BACKGROUND: In 2021, the Uppsala Monitoring Center of the World Health Organization included 52 vaccines for coronavirus disease-2019 (COVID-19) prevention in the international database, VigiBase, and almost immediately, this group of medicines (drugs) took the lead in the increased rate of reported adverse reactions (ARs). AIM: This study aimed to review the case reports of ARs from COVID-19 vaccines in the VigiBase database. MATERIALS AND METHODS: Statistical analysis of cases that describe ARs in the international pharmacovigilance VigiBase database was performed. RESULTS: On May 12, 2021, the VigiBase database included 26,099,906 reports that describe AR cases on drugs, including 585,744 reports of AR on vaccines for COVID-19 prevention. Serious ARs after immunization with these vaccines were registered in 31.5% of reports, including 0.9% fatal and 1.3% life-threatening. Headache (37.1% of reports), pyrexia (31.1%), chills (23.2%), and fatigue (22.7%) were most frequently recorded. CONCLUSIONS: More data are required to confirm the association between the COVID-19 vaccines and the increased risk of ARs following their use.

  • Open Access

    New pharmacological effects of caripazim

    by German V. Kukushkin, Marina V. Zhuravleva, Lyudmila P. Sviridkina, Dmitry E. Yurov

    The effects of a proteolytic enzyme found in papaya milk juice (caripazim) on the rate of lymphatic drainage of tissues and the pharmacokinetics of cefotaxime were studied in experiments on rabbits and mice. During the study, caripazim was administered to experimental animals, and the rate of removal of Evans blue from the mesentery of mice, as well as the concentration of cefotaxime over time in the blood plasma of rabbits and the blood plasma, intestinal tissues, and livers of mice, after 1.5 and 24 h of antibiotic administration following injection of caripazim, were determined. Thus, the lymphostimulatory properties of caripazim were revealed. Its preliminary administration increased the concentration of cefotaxime in the blood plasma of rabbits in comparison with single administration of an antibiotic at all points of the study (1.5, 3, 4.5, 6, 8, 12, and 24 h). This coincides with the data from the study of the level of antibiotic in the blood plasma of mice. Administration of cefotaxime after injection of caripazim leads to an increase in its content in the intestinal tissue, after both 1.5 and 24 h, but does not affect at the accumulation of the antibiotic in the liver. The concentration ratio liver tissue / blood in mice in the main group was significantly lower than that in the control group, both 1.5 and 24 h into the experiment, which indirectly indicates a decrease in hepatic antibiotic extraction. The data obtained indicates that caripazim has the properties of an endolymphatic conductor.

  • Open Access

    Drug Safety for Children — International Monitoring Data for 50 Years

    by B. K. Romanov, Yu. V. Olefir, R. N. Alyautdin, S. V. Glagolev, V. A. Polivanov, L. I. Ilienko, S. P. Alpatov, N. V. Bogush, N. M. Buyanova, I. V. Ganshina, et al.

    Безопасность применения лекарственных средств у детей — данные международного мониторинга за 50 лет